SG11201502937PA - COMBINATION THERAPIES USING ANTI-<i>PSEUDOMONAS</i> PSL AND PCRV BINDING MOLECULES - Google Patents

COMBINATION THERAPIES USING ANTI-<i>PSEUDOMONAS</i> PSL AND PCRV BINDING MOLECULES

Info

Publication number
SG11201502937PA
SG11201502937PA SG11201502937PA SG11201502937PA SG11201502937PA SG 11201502937P A SG11201502937P A SG 11201502937PA SG 11201502937P A SG11201502937P A SG 11201502937PA SG 11201502937P A SG11201502937P A SG 11201502937PA SG 11201502937P A SG11201502937P A SG 11201502937PA
Authority
SG
Singapore
Prior art keywords
psl
pseudomonas
binding molecules
combination therapies
pcrv binding
Prior art date
Application number
SG11201502937PA
Other languages
English (en)
Inventor
Antonio Digiandomenico
Paul Warrener
Charles Stover
Bret Sellman
Ralph Minter
Sandrine Guillard
Steven Rust
Vignesh Venkatraman
Reena Varkey
Li Peng
Melissa Damschroder
Partha Chowdhury
Nazzareno Dimasi
Ryan Fleming
Binyam Bezabeh
Changshou Gao
Mladen Tomich
Original Assignee
Medimmune Llc
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc, Medimmune Ltd filed Critical Medimmune Llc
Publication of SG11201502937PA publication Critical patent/SG11201502937PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201502937PA 2012-11-06 2013-11-06 COMBINATION THERAPIES USING ANTI-<i>PSEUDOMONAS</i> PSL AND PCRV BINDING MOLECULES SG11201502937PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723192P 2012-11-06 2012-11-06
PCT/US2013/068609 WO2014074528A2 (fr) 2012-11-06 2013-11-06 Polythérapies à l'aide de molécules de liaison anti-pseudomonas psl et pcrv

Publications (1)

Publication Number Publication Date
SG11201502937PA true SG11201502937PA (en) 2015-06-29

Family

ID=50685302

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201502937PA SG11201502937PA (en) 2012-11-06 2013-11-06 COMBINATION THERAPIES USING ANTI-<i>PSEUDOMONAS</i> PSL AND PCRV BINDING MOLECULES

Country Status (11)

Country Link
US (1) US20150284450A1 (fr)
EP (1) EP2917236A2 (fr)
JP (1) JP2015535005A (fr)
KR (1) KR20150082367A (fr)
CN (1) CN104995209A (fr)
AU (1) AU2013341349A1 (fr)
BR (1) BR112015010240A2 (fr)
CA (1) CA2888211A1 (fr)
MX (1) MX2015005719A (fr)
SG (1) SG11201502937PA (fr)
WO (1) WO2014074528A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038509T2 (hu) 2011-06-10 2018-10-29 Medimmune Ltd Pseudomonas PSL elleni kötõmolekula és alkalmazása
JP6182152B2 (ja) * 2011-11-07 2017-08-16 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
MX2017014002A (es) 2015-05-01 2018-08-01 Inhibrx Lp Moléculas de direccionamiento del sistema de secreción tipo iii .
PL3322734T3 (pl) 2015-07-16 2021-05-04 Inhibrx, Inc. Wielowartościowe i wielospecyficzne białka fuzyjne wiążące się z DR5
CN108368149A (zh) * 2015-11-30 2018-08-03 免疫医疗有限公司 用于预防或治疗医源性肺炎的方法
SG11201809778TA (en) * 2016-05-05 2018-12-28 Univ Pennsylvania Dna antibody constructs for use against pseudomonas aeruginosa
RU2020112725A (ru) * 2017-10-02 2021-11-08 Аридис Фармасьютикалс, Инк. Композиции и способы для борьбы с инфекциями, вызванными синегнойной палочкой (pseudomonas aeruginosa)
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
KR20220019755A (ko) * 2019-06-11 2022-02-17 리제너론 파마슈티칼스 인코포레이티드 PcrV에 결합하는 항-PcrV 항체, 항-PcrV 항체를 포함하는 조성물, 및 이의 사용 방법
JP7478807B2 (ja) * 2019-07-09 2024-05-07 北京三▲諾▼佳邑生物技▲術▼有限▲責▼任公司 シュードモナス菌ＰｃｒＶを特異的に認識する抗体及びその使用
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN114072145B (zh) * 2020-06-01 2024-06-11 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv的抗体及其用途
CN116693680A (zh) * 2020-08-07 2023-09-05 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌psl的抗体及其用途
WO2022105818A1 (fr) * 2020-11-18 2022-05-27 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Combinaisons d'anticorps et d'anticorps bispécifiques comprenant une liaison à l'antigène reconnaissant de manière spécifique pseudomonas pcrv et psl
TW202417478A (zh) 2022-06-29 2024-05-01 瑞典商阿斯特捷利康公司 用於治療支氣管擴張的抗PcrV和Psl雙特異性藥物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE272116T1 (de) * 1996-06-24 2004-08-15 Zlb Bioplasma Ag Polypeptide mit der möglichkeit rhesus d antigenspezifische bindungsstrukturen aus zu bilden, dafür kodierende dna und deren prozess der herstellung und anwendung
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
MXPA06001634A (es) * 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
KR100918746B1 (ko) * 2004-09-06 2009-09-24 교와 핫꼬 기린 가부시키가이샤 항 ａ３３ 항체
TW200636066A (en) * 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
US7910703B2 (en) * 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2009073631A2 (fr) * 2007-11-30 2009-06-11 Kalobios Pharmaceuticals, Inc. Anticorps dirigés contre l'antigène pcrv de pseudomonas aeruginosa
ES2828627T3 (es) * 2008-04-25 2021-05-27 Kyowa Kirin Co Ltd Anticuerpo multivalente estable
EP2356270B1 (fr) * 2008-11-07 2016-08-24 Fabrus Llc Bibliothèques combinatoires d'anticorps et leurs utilisations
SG10201600899PA (en) * 2011-02-08 2016-03-30 Medimmune Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
HUE038509T2 (hu) * 2011-06-10 2018-10-29 Medimmune Ltd Pseudomonas PSL elleni kötõmolekula és alkalmazása
JP6182152B2 (ja) * 2011-11-07 2017-08-16 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療

Also Published As

Publication number Publication date
AU2013341349A8 (en) 2015-12-03
WO2014074528A8 (fr) 2015-05-21
CN104995209A (zh) 2015-10-21
AU2013341349A1 (en) 2015-05-21
CA2888211A1 (fr) 2014-05-15
KR20150082367A (ko) 2015-07-15
EP2917236A2 (fr) 2015-09-16
BR112015010240A2 (pt) 2017-08-22
WO2014074528A3 (fr) 2014-07-03
US20150284450A1 (en) 2015-10-08
MX2015005719A (es) 2016-01-12
WO2014074528A2 (fr) 2014-05-15
JP2015535005A (ja) 2015-12-07

Similar Documents

Publication Publication Date Title
SG11201502937PA (en) COMBINATION THERAPIES USING ANTI-&lt;i&gt;PSEUDOMONAS&lt;/i&gt; PSL AND PCRV BINDING MOLECULES
IL260189A (en) Communicating molecules for bcma and cd3
HK1201453A1 (en) Combination therapies using anti- pseudomonas psl and pcrv binding molecules psl pcrv
HK1257190A1 (zh) 抗假單胞菌psl結合分子及其用途
KR101581655B9 (ko) 세포 내 관통능을 가지고 ｒｎａ 간섭을 유도하는 핵산 분자 및 그 용도
EP2931319A4 (fr) Molécules d&#39;acide nucléique modifiées et leurs utilisations
EP2585595B8 (fr) Molécules d&#39;arn et leurs utilisations
ZA201307302B (en) Cd37-binding molecules and immunoconjugates thereof
PL3650125T3 (pl) Rozpylacz cieczy i sposoby
ZA201300930B (en) St-246 liquid formulations and methods
GB201219487D0 (en) Anti-S100A4 antibody molecules and their uses
HK1211055A1 (en) New cell-specifically active nucleotide molecules and application kit for the application thereof
GB201015790D0 (en) Thrombin-binding antibody molecules and uses thereof
AU2011904605A0 (en) Adiposity-modulating molecules and uses therefor
AU2012904469A0 (en) Wastewater refinery
AP2014007497A0 (en) Binding molecules for BCMA and CD3
GB201014118D0 (en) Assay molecules
GB201014117D0 (en) Assay molecules